The present era of individualized medicine mandates a screening of anti-ERR molecules alone or in combination with aromatase inhibitors (e.g., anastrozole), SERMs (e.g., tamoxifen) or SERDs (e.g., fulvestrant) in a specific NSCLC type. This evidence concerns the gene SLC7A1 and non-small cell lung carcinoma.